USE OF HIGHER DOSE EXTENDED INTERVAL AMINOGLYCOSIDES IN A NEONATAL INTENSIVE CARE UNIT

ABSTRACT

The objective of this study is to determine the safety and efficacy of an extended interval aminoglycoside dosing guideline implemented in our neonatal intensive care unit (NICU). A retrospective review of pharmacokinetic data on 44 patients led to the development of an extended interval aminoglycoside guideline utilizing a 5-mg/kg dose given at an interval based on postconceptional age and risk factors that may alter aminoglycoside clearance. After implementation of the new clinical guideline, a retrospective review of patient records was performed. Thirty-six of 43 peak levels were within the goal range. Trough levels were < 1 μg/mL in 41 of 46 patients, with no trough > 2 μg/mL. Thirty-three patients had clinical or culture proven sepsis and were successfully treated with the new regimen. No difference between pre- and posttreatment blood urea nitrogen (BUN) and serum creatinine values was observed. Hearing evaluations were performed in 32 patients with one failure. The patient who failed the hearing screen, passed a follow-up hearing test. Three deaths, none attributed to infection or the drug, occurred during the evaluation period. The dosing guidelines developed for our NICU patients are safe and effective, although evaluation of the long-term potential for ototoxicity should be performed.

KEYWORD

Neonates - aminoglycosides - dosing guidelines

REFERENCES

• 1 Stopnik H, Wallraf R, Nies B, Troster K, Heimann G. Pharmacokinetics and antibacterial activity of daily gentamicin.  Arch Dis Child . 1992;  67 57-61
• 2 Stopnik H, Heimann G. Once daily aminoglycoside dosing in full term neonates.  Pediatr Infect Dis J . 1995;  14 71-72
• 3 Capers C C, Gregory D F, Herzog C C. Optimal gentamicin dosing in neonates.  Ann Pharmacother . 1995;  29 430-431
• 4 Hayani K C, Hatzopoulos F K, Frank A L. Pharmacokinetics of once-daily dosing of gentamicin in neonates.  J Pediatr . 1997;  131 76-80
• 5 de Alba Romero C, Castillo E G, Secades D M. Once daily gentamicin dosing in neonates.  Pediatr Infect Dis J . 1998;  17 1169-1171
• 6 Thureen P J, Reiter P D, Gresores A. Once- versus twice-daily gentamicin dosing in neonates ≥ 34 weeks gestation: cost-effectiveness analyses.  Pediatrics . 1999;  103 594-598
• 7 Lundergan F S, Glasscock G F, Kim E H, Cohen R S. Once-daily gentamicin dosing in newborn infants.  Pediatrics . 1999;  103 1228-1234
• 8 Moore R D, Lietman P S, Smith C R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.  J Infect Dis . 1987;  155 93-99
• 9 Moore R D, Smith C R, Lietman P S. The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia.  J Infect Dis . 1984;  149 443-448
• 10 Daikos G L, Jackson G G, Lolans V T, Livermore D M. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation.  J Infect Dis . 1990;  162 414-420
• 11 Chayasirisobhon S, Yu L, Griggs L. Recording of brainstem evoked potentials and their association with gentamicin in neonates.  Pediatr Neurol . 1996;  14 277-280